Want to see GANX full AI Analyst Report?
GANX Stock Chart & Stats
$1.75
-$0.07(-3.85%)
At close: 4:00 PM EDT
$1.75
-$0.07(-3.85%)
Day’s Range― - ―
52-Week Range$1.53 - $4.34
Previous Close$1.75
Volume471.96K
Average Volume (3M)1.07M
Market Cap
$86.41M
Enterprise Value$74.57
Total Cash (Recent Filing)$13.08M
Total Debt (Recent Filing)$609.87K
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Nov 18, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding43,643,620
10 Day Avg. Volume710,440
30 Day Avg. Volume1,073,672
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)5.72
Price to Sales (P/S)0.00
P/FCF Ratio-5.75
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.20Price Target Upside311.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.51
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 2 Parkinson’s DevelopmentFDA authorization materially advances the lead program beyond early development and enables larger efficacy testing in Parkinson’s patients, creating a clearer path to clinical validation and potential future partnering or commercialization.
Clinical And Biomarker SupportSustained participation, favorable tolerability, and biomarker improvement provide a foundation for continued development. These findings may support the disease-modifying rationale, although confirmation in controlled studies remains necessary.
Funding Runway And Low LeverageFunding into Q2 2027 and limited debt give Gain time to execute planned clinical milestones without immediate financing pressure. This improves operational flexibility, though continued development will still require disciplined cash management.
Bears Say
No Meaningful RevenueThe absence of meaningful revenue shows that Gain remains dependent on clinical progress rather than commercial operations. Until a product or partnership generates sales, the company has limited internal funding capacity and high execution risk.
Persistent Net LossesLarge recurring losses across multiple years indicate that profitability is not near term and that operating expenses will remain substantial as trials progress. Continued losses can constrain strategic options and increase reliance on external capital.
Heavy Cash Burn And Funding RiskPersistent operating and free-cash-flow deficits mean the business is not self-funding. Even with runway into 2027, ongoing trial costs may require future equity or other financing, creating dilution risk and dependence on capital-market access.
Gain Therapeutics News
GANX FAQ
What was Gain Therapeutics, Inc.’s price range in the past 12 months?
Gain Therapeutics, Inc. lowest stock price was $1.53 and its highest was $4.34 in the past 12 months.
What is Gain Therapeutics, Inc.’s market cap?
Gain Therapeutics, Inc.’s market cap is $86.41M.
When is Gain Therapeutics, Inc.’s upcoming earnings report date?
Gain Therapeutics, Inc.’s upcoming earnings report date is Nov 18, 2026 which is in 87 days.
How were Gain Therapeutics, Inc.’s earnings last quarter?
Gain Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.138 by $0.028.
Is Gain Therapeutics, Inc. overvalued?
According to Wall Street analysts Gain Therapeutics, Inc.’s price is currently Undervalued.
Does Gain Therapeutics, Inc. pay dividends?
Gain Therapeutics, Inc. does not currently pay dividends.
What is Gain Therapeutics, Inc.’s EPS estimate?
Gain Therapeutics, Inc.’s EPS estimate is -0.12.
How many shares outstanding does Gain Therapeutics, Inc. have?
Gain Therapeutics, Inc. has 43,643,620 shares outstanding.
What happened to Gain Therapeutics, Inc.’s price movement after its last earnings report?
Gain Therapeutics, Inc. reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.138. Following the earnings report the stock price went up 16.384%.
Which hedge fund is a major shareholder of Gain Therapeutics, Inc.?
Currently, no hedge funds are holding shares in GANX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gain Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (311.43% Upside)
$7.20 (311.43% Upside)
Blogger Sentiment
Bullish
GANX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
10.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
56.82%
Trailing 12-Months
Company Description
Gain Therapeutics, Inc.
Gain Therapeutics, Inc. is a biotechnology firm specializing in the creation of advanced treatments for conditions originating from improperly folded proteins. The company primarily directs its efforts towards rare genetic disorders and neurological ailments. It employs its unique Site-Directed Enzyme Enhancement Therapy (SEE-Tx) platform to pinpoint specific allosteric sites on malformed proteins. Subsequently, Gain Therapeutics identifies proprietary small molecules designed to bind to these locations, thereby restoring correct protein conformation and alleviating the disease. Their current development pipeline includes several structurally targeted allosteric regulator candidates aimed at combating a range of diseases, such as Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1. Established in 2017, the company is headquartered in Bethesda, Maryland.
GANX Stock 12 Month Forecast
Average Price Target
$7.20
▲(311.43% Upside)
Technical Analysis
Ownership Overview
2.23%
Insiders
1.72% Mutual Funds
3.85% Other Institutional Investors
90.69% Public Companies and
Individual Investors